Skip to content
  • Pipeline
    • Pipeline overview
    • Clinical development
    • Drug delivery technology
  • News
  • About us
    • Team
    • Advisory Board
    • Board of Directors
  • Contact
  • Pipeline
    • Go back
    • Pipeline overview
    • Clinical development
    • Drug delivery technology
  • News
  • About us
    • Go back
    • Team
    • Advisory Board
    • Board of Directors
  • Contact

Uncategorized

Bukwang initiates dosing of JM-010 in Europe phase 2 study

Posted on 10. January 2020

Contera Pharma attracts investment from Medici Investment

Posted on 10. July 2019

Commencement of Phase 2 Clinical Study of JM-010 in major European countries

Posted on 26. June 2019

Clinical Trial Application approved by European authority to initiate Phase 2 study of JM-010

Posted on 22. October 2018

Bukwang registered patents on a therapeutic candidate for Levodopa-induced dyskinesia in Parkinson’s disease

Posted on 31. January 2018

JM-010 approved for Orphan Drug Designation

Posted on 5. January 2017

Press release, JM-010CS01, Phase IIa/cPoC study

Posted on 7. September 2016

US patent covering JM-010 for treatment of movement disorders has been granted

Posted on 6. November 2015

Press release, JM-010CS01, Phase IIa/cPoC study

Posted on 15. June 2015

Solural Pharma and Contera Pharma initiate Eurostar sponsored project in Parkinson’s disease

Posted on 1. May 2015

Posts pagination

Previous 1 2 3 4 Next

Contera Pharma ApS

Venlighedsvej 4

2970 Hørsholm

Denmark

Thomas Sager, CEO
info@conterapharma.com

  • Pipeline
  • News
  • About us
  • Contact
2026 Contera Pharma

Cookie & privacy policy

Whistleblower